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To develop new avenues for synthesizing novel antidotes for organophosphate poisoning and for detection 
of the organophosphates, we have turned to recombinant DNA methods to synthesize cholinesterases with 
unusual properties. For antidotal therapy we describe mutations of the native mouse and human enzymes 
that allow for enhanced rates of oxime reactivation. Such enzymes, when localized in the circulation, would 
enable the circulating cholinesterase to become a catalytic rather than simply a stoichiometric scavenger. 
Hence, “oxime-assisted catalysis” provides a means for scavenging the organophosphates in the circulation 
thereby minimizing their tissue penetration and toxicity. Accordingly, the oxime antidote or prophylactic 
agent has a dual action within the circulation and at the tissue level. Second, through a novel chemistry, 
termed freeze-frame, click chemistry, we have used organophosphate conjugates of acetylcholinesterase 
as templates for the synthesis of novel nucleophilic reactivating agents. Finally, acetylcholinesterase can 
be modified through cysteine substitution mutagenesis and attachment of fluorophores at the substitution 
positions. When linked at certain locations in the molecule, the attached fluorophore is sensitive to 
organophosphate conjugation with acetylcholinesterase, and thus the very target of insecticide or nerve 
agent action becomes a detection molecule for organophosphate exposure.
KEY WORDS: acetylcholinesterase, fluorescent acetylcholinesterase, organophosphate inhibitors, oxime 
antidotes, oxime-assisted catalysis, reactivation kinetics, remote detection, in situ - click chemistry, 
template-guided drug design
* Partly presented at the EUROTOX 2006/6 CTDC Congress – Symposium on Molecular Mechanisms of Organophosphates, Cavtat, 
Croatia, 20-24 September 2006.
Over the last decade, developing means for 
detection of organophosphates and synthesizing new 
antidotes or prophylactic agents for organophosphate 
exposure have been accorded considerable 
attention (1, 2). This arises more out of concern of 
organophosphates being used in terrorism, rather 
than their applicability as chemical warfare weapons. 
Even in the absence of such insidious threats, 
organophosphate pesticides remain in widespread use 
in the home, garden and agricultural industry across 
the globe. Accessibility of these compounds thus 
warrants consideration of new chemical approaches 
to their detection and antidotal therapy following 
inadvertent exposure. In contrast to many compounds 
considered in threatened or actual terrorism or in use 
as pesticides, the organophosphates are directed to a 
discrete target of known structure at atomic resolution 
and have a well-defined mechanism of action (2, 3).
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Advances in antidotal therapy have largely arisen 
from the original concepts of Irwin Wilson and his 
colleagues over 50 years ago, when he described the 
principles of site-directing nucleophiles to the active 
centre of the enzyme to break the phosphoester 
bond in the conjugated enzyme (Figure 1) (4). It 
was this approach that led to the development of 
the first pyridinium aldoxime (2-PAM) used as an 
antidote in organophosphate poisoning. Over the 
intervening years, some improvements have occurred 
in the development of other oximes and the use of a 
combination of muscarinic antagonists and seizure 
suppressing agents to control symptoms. Despite 
the developments in cloning the AChE gene (5-7), 
and the determination of the structure of the enzyme 
(8, 9) from several sources, this structural information 
has yet to be fully applied to the development of 
superior antidotes or detection agents (2). We show 
here how structure might guide the development of 
selective cholinesterase inhibitors, novel reactivating 
agents and organophosphate exposure detectors. 
The approach relies heavily on core structural 
information from crystallography, enhanced by 
detailed information on the structural dynamics of 
the target derived from mutagenesis, computational 
and physical measurements of the dynamics of the 
molecule (10-12).
Development of Novel Ligands Through Freeze-
Frame, Click Chemistry
Through collaboration with Dr. Barry Sharpless’ 
group and through the use of the click chemistry 
methods developed in that laboratory (13), we have 
employed the AChE template for the design of 
selective inhibitors based on peripheral site (propidium 
derivatives) and active centre inhibitors (acridine 
derivatives) as building blocks. This approach relies 
on a bioorthogonal reaction between an acetylene and 
an azide; both are tethered through reversible binding 
to separate sites on the molecule to form a stable 
triazole (Figure 2). By combinatorial syntheses, great 
selectivity can be acquired in terms of regional isomers 
of the four possible substituted triazoles and the chain 
length between anchoring positions on the acetylene 
and azide building blocks. Hence, we can start with 
libraries of building blocks, allow the reaction to 
occur on the very target of drug action as the reaction 
vessel, and isolate the products formed by mass 
spectrometry. Although, as expected, the reaction 
occurs with one to one stoichiometry on the template, 
the higher molecular weight reaction product can be 
isolated from the reaction mix and easily identified 
by mass spectrometry (13). The studies revealed the 
selectivity of the reaction in terms of syn versus anti
preferences. Moreover, the inhibitors formed on the 
template reveal the capacity to select unique or minor 
abundance conformations of AChE in the formation 
of the high affinity complex (14). Refinement of 
building block molecules has yielded cholinesterase 
inhibitors with Kd values approaching 1 fmol L
-1 to 2 
fmol L-1, a value that can only be measured accurately 
through the kinetics of association and dissociation. 
Figure 1 Reaction cycle for alkyl phosphate hydrolysis catalyzed by acetylcholinesterase and an oxime. Shown here are the phosphorylation step 
rendering the enzyme inactive followed by reactivation spontaneously or promoted by an administered oxime. In addition, an aging
reaction can occur where the conjugate loses an alkoxy group rendering it largely resistant to oxime reactivation
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Other refinements have eliminated the quaternary 
groups in the building blocks and diminished their 
size to allow blood-brain barrier penetration (15). In 
addition, by developing building blocks where steric 
clearance in the acyl pocket of the active centre is 
altered, specificity toward the insect AChE versus the 
mammalian AChE can be achieved (16).
To use this approach in the development of 
superior reactivating agents, one should consider 
several strategies. First, the template for the reaction 
might be the AChE-organophosphate conjugate, 
instead of the apo-enzyme in the case of inhibitor 
development (Figure 3). Although the triazole inhibitors 
form rapidly on the enzyme surface, the more stable 
organophosphate conjugates should be used as 
templates for this purpose. Accordingly our initial 
approach has involved synthesis of binding blocks 
for triazole formation or the triazole itself containing 
an oxime moiety. Variations on this theme will be to 
expand from the pyridinium aldoxime template to less 
space impacting nucleophiles.
A second consideration is based on the structural 
template of AChE in relation to the mechanisms of 
organophosphate reaction with the active centre 
of AChE and the subsequent reactivation reaction. 
The initial demonstration of a narrow and somewhat 
torturous gorge of some 18 Å to 20 Å in depth (8) poses 
a challenge particularly for the nucleophilic reactivation 
step forming active enzyme. Organophosphates, upon 
entering the gorge, orient their reactive groups such 
that the phosphoryl or phosphonyl oxygens associate 
with and become polarized by the oxyanion hole. 
This facilitates attack in a SN2-like mechanism by the 
active centre serine. By contrast, in the reactivation 
reaction, the narrow gorge is further impacted by 
Figure 2 Reaction of the acetylene and azide building blocks to form 
syn- and anti-triazole inhibitors of acetylcholinesterase
Figure 3 Proposed reaction between a peripheral site (PAS) extended acetylene (phenyl phenanthridinium linked to the acetylene through a methylene 
chain) and a 2-hydroxyiminomethyl-N-3-azidopropyl pyridinium. A mode of the positioning of these residues within the AChE active
centre gorge is also depicted. The arrow indicates the entrance to the gorge. A) 2-hydroxyiminomethyl-N-3-azidopropyl pyridinium oxime 
(m=3 in the formula below) bound at the base of the gorge. B) Ternary complex between the oxime and the PAS bound acetylene (n=5
in the formula below) in the gorge. C) The hypothetical in situ acetylene + azide cycloaddition reaction product (m=3, n=5) formed in 
the AChE active centre gorge.
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the conjugated organophosphate. Accordingly, the 
reactivation reaction cannot proceed by the hindside 
attack of the SN2 mechanism. This sub-optimal 
geometry likely accounts for the greatly diminished 
efficiency of the oxime reactivation reaction compared 
to inactivation, despite site directing the nucleophile 
to the active centre by virtue of the cationic charge 
and its spatial proximity to the active centre serine (4, 
17, 18). It is this consideration upon which “oxime-
assisted catalysis” of the offending organophosphate 
by a modified AChE is based.
Oxime-assisted Catalysis
To enhance the angle of access to the conjugated 
organophosphate, one might first turn to the acyl 
pocket region found in AChE to be lined with two 
phenylalanine side chains (Phe 295 and 297). In 
butyrylcholinsterase we find a leucine and isoleucine 
residues at those positions. The smaller and more 
flexible aliphatic side chains should provide greater 
space for the organophosphate as it does for acyl 
esters larger than propionylcholine. Similarly, one 
might expect diminished impaction with the entry of 
the oxime. However, the situation appears to be not 
that simple, for we find in many cases that oxime 
reactivation of organophosphates conjugated with 
BChE is slower than with AChE. Therefore, we began 
to dissect the residues contributing to the acyl pocket 
to ascertain whether we could enhance the reactivation 
reaction, thereby obtaining greater catalytic efficiency 
in cholinesterases hydrolyzing organophosphates.
Because of gorge impaction, the enhanced 
catalytic turnover of organophosphates can be 
expected to depend on three structural factors:
(i) the dimensions of the active centre of the 
enzyme and the gorge entry portal that will affect 
clearance of the entering oxime and the positioning 
of the conjugated organophosphate. From studies 
with SP and RP alkyl methylphosphonates conjugated 
to the active centre of AChE, it is clear that occupation 
of the oxyanion hole, as in the case for inactivation, 
is essential for substantive reactivation efficiency 
(19-21). Therefore, upon nucleophilic attack, the 
conjugated organophosphate should be positioned 
so that the phosphonyl or phosphoryl bond can be 
polarized by the oxygen entry into the oxyanion hole. 
Gorge dimensions and positions of the critical residues 
can be, in part, modified through mutagenesis.
(ii) the structure of the organophosphate 
conjugate. The importance of this factor is evident 
from studies of the RP and SP methylphosphonate 
enantiomers (19-21), and from using various alkyl 
methylphosphonates and dialkyl phosphorates 
with alkyl groups of various sizes (22). For the 
organophosphates with larger alkyl groups, enlarging 
gorge dimensions through changing acyl pocket 
size influences reactivation of the more bulky 
organophosphates relative to the smaller one. This 
becomes evident from a comparison of reactivation 
of cycloheptyl and isopropyl methyl phosphonates.
(iii) the structure of the oxime or other candidate 
reactivating nucleophile. Here again, one can affect 
the attacking angle of the nucleophile by altering the 
distance between the nucleophile and the quaternary 
amine moiety. In other cases, one may wish to 
minimize the bulk in a 6-membered and incorporate 
4- or 5-membered rings or to develop linear cationic 
nucleophiles. Passage across the blood-brain barrier 
might be achieved with bases of moderate pKa (8 to 
9) and with ligands where the basic group is spread 
over resonance and conjugation such as the case of 
the amidines (23).
To demonstrate proof of principle, we have carried 
out mutations of several residues in the active centre of 
mouse and human AChE, and examined the capacity 
for oximes to reactivate AChE conjugated by various 
SP and RP isopropyl, cycloheptyl and 3,3-dimethylbutyl 
methylphosphonates (Table 1). Enhancements of rates 
can be achieved by enlarging the acyl pocket through 
the substitution of aliphatic residues and enhancing 
clearance on the choline-occupying domain of the 
active centre, Tyr 337 (22). In fact, the combination 
of these mutations on the two sides of the gorge is 
the most successful (22), and ∼120-fold increase 
in oxime-assisted catalytic turnover is achieved with 
SP-cycloheptyl methylphosphonothiocholine. An 
analysis of the kinetics shows the rate-limiting step 
to be the oxime attack. Thus, our analysis can be 
independent of leaving group of the organophosphate 
used to form the conjugate. More detailed kinetic 
studies have been conducted to ascertain whether 
the mutations influence the affinity of the initial oxime 
complex, Kox, or the intrinsic rate of oxime attack, kcat,
to break the phosphorus-oxygen bond.
It remains to be seen how far prospective 
mutagenesis will yield in enhanced rates for the 
various nerve agents that conjugate with the 
organophosphates, and a study varying the three 
parameters alluded to above is underway as a 
combined endeavour between groups in the United 
States, Croatia and Germany. Mutagenesis selection 
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procedures involving somatic cell hypermutation 
provide an alternative approach of enhancing 
organophosphate catalysis (23).
Acetylcholinesterase as a Detector of 
Organophosphate Exposure
Recombinant DNA methods can also be used to 
modify AChE so that a chromophoric side chain is added 
to the enzyme at a position that changes conformation 
upon conjugation by an organophosphate or binding 
of a reversible inhibitor. Selection of the position for 
addition of the chromophoric side chain is critical, 
and this can be pursued by cysteine substitution 
mutagenesis through out the molecule. The omega 
loop, between residues 69 and 96 in mammalian 
cholinesterase is a good example, since this loop 
appears to cap the active centre gorge. Labelling 
residues distant from the site of binding results in a 
conformational change. For example, substitution 
of a cysteine at position 81 or 84 allows one to label 
the enzyme with a sulfhydryl modifying fluorophore 
such as acrylodan or a fluorescein derivative. Upon 
conjugation of the organophosphate characteristic 
changes in the fluorescence emission spectrum are 
evident. In some cases the spectral change is sensitive 
to the size and stereochemical characterisation of the 
organophosphate (24). This application is discussed 
in more depth in other reviews (2), and is applicable 
to measurements of decay of anisotropy to measure 
torsional, segmental and global motion in the 
macromolecule (25).
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Sa`etak
PRIMJENA TEHNOLOGIJE REKOMBINANTNE DNA ZA PRIPRAVKE KOLINESTERAZA KAO ANTIDOTA 
I DETEKTORA ORGANOFOSFATA
Razvijaju}i novi pristup sintezi antidota pri otrovanju organofosfatima kao i njihovu detekciju, primijenili smo 
metode rekombinantne DNA za pripremu kolinesteraza s neuobi~ajenim svojstvima. Za antidotsku terapiju 
istra`ili smo mutacije prirodnih enzima mi{a i ~ovjeka koje pove}avaju brzine reaktivacije oksimom. Takvi 
enzimi bi po unosu u cirkulaciju postali kataliti~ki, a ne samo stehiometrijski odstranjiva~i organofosfata. 
Na taj na~in “oksimom potpomognuta kataliza” omogu}ava ~i{}enje organofosfata iz cirkulacije umanjuju}i 
prodiranje organofosfata u tkiva i njihovu toksi~nost. Prema tome, oksim kao antidot ima dvojaku ulogu: 
u cirkulaciji i na razini tkiva. S druge strane, uporabom novog sintetskog pristupa u oblikovanju biolo{ki 
aktivnih spojeva poznatog kao “klik kemija” diskretnih proteinskih konformacija, organofosforilirani konjugati 
acetilkolinesteraze slu`e kao kalup u sintezi novih nukleofilnih reaktivatora. Naposljetku, acetilkolinesteraza 
se mo`e mutagenezom modificirati uvo|enjem cisteina na koje se mogu vezati fluorofori. Fluorofori uvedeni 
na odre|ena mjesta u molekuli acetilkolinesteraze mijenjaju svoja fluorescentna svojstva pri konjugaciji 
organofosfata s enzimom koji na taj na~in od objekta djelovanja insekticida i ̀ iv~anih bojnih otrova postaje 
molekula za detekciju izlo`enosti organofosfatima.
KLJU^NE RIJE^I: acetilkolinesteraza, antidoti, detekcija, fluorescentna acetilkolinesteraza, in situ - klik 
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